Galunisertib During Normothermic Machine Perfusion Attenuates Profibrotic Signaling in Discarded Human Donor Kidneys
Year: 2026
Type: article
Abstract: INTRODUCTION: Early-onset fibrosis limits kidney transplant success, causing early allograft failure in up to 50% of deceased donor kidneys within 10 years or excluding many from transplantation. Normothermic machine perfusion (NMP) offers a platform for targeted drug delivery to isolated organs, minimizing systemic effects. This study evaluated whether galunisertib modulates fibrosis-associated molecular signaling when administered to discarded human kidneys during ex vivo NMP, while assessing treatment safety and pharmacokinetics. METHODS: Twelve discarded human kidneys underwent 4 h of oxygenated hypothermic perfusion followed by 6 h of NMP with galunisertib or vehicle (n = 6). Precision-cut kidney slices (PCKS) were then cultured for 48 h with either continued or discontinued galunisertib exposure. Endpoints included fibrosis-related mRNA expression and pharmacokinetics. RESULTS: Galunisertib was administered during NMP and steadily excreted in urine without adverse effects on organ function. Continued exposure in PCKS significantly attenuated fibrosis-related mRNA expression, including SERPINE1 (24 h: p = 0.0057; 48 h: p = 0.0046). Discontinuation increased ACTA2 expression (p = 0.0156), while continued treatment prevented this phenomenon (p = 0.0014). CONCLUSION: NMP enabled targeted delivery of galunisertib to discarded human kidneys without detectable adverse effects on ex vivo renal function. Prolonged galunisertib exposure was associated with modest attenuation of fibrosis-associated molecular markers during subsequent tissue culture. These findings provide proof-of-concept for pharmacological modulation of profibrotic signaling during ex vivo kidney perfusion.
Source: Artificial Organs
DOI: 10.1111/aor.70281
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,990
OpenAlex ID: W4412862943
